Wish Dhillon, Medical Oncologist at AZCCC/Honor Health, shared on X:
“Grateful for the chance to chair the Genitourinary Cancer session at Binaytara’s 2026 Tucson Annual Conference on Advances in Hematology and Oncology.
Thank you to Dr. Neda Hashemi (Prostate Cancer), Dr. Irbaz Riaz (Bladder Cancer), and Dr. Alejandro Recio-Boiles (Kidney Cancer) for excellent presentations.
A few takeaways and ongoing conversations with colleagues:
- Bladder – already changing practice. KEYNOTE-B15 / EV-304 showed that perioperative enfortumab vedotin plus pembrolizumab improved event-free survival versus neoadjuvant gemcitabine-cisplatin (HR 0.53;
- Median not reached versus 48.5 months), improved overall survival (HR 0.65), and raised pathologic complete response from 32.5% to 55.8% in cisplatin-eligible MIBC. This trial was clearly the highlight of the session!
–
- Prostate – TALAPRO-3 and the case for universal NGS. TALAPRO-3 supported early talazoparib plus enzalutamide in HRR-altered metastatic castration-sensitive disease (rPFS HR ~0.48; clearer benefit in BRCA).
- The practical implication is bigger than one regimen: if biomarker-directed intensification starts at diagnosis of metastatic disease, all patients with metastatic prostate cancer should get next-generation sequencing then – germline and tumor/ctDNA – not late in the course.
–
- Prostate Cancer- two debates, not settled algorithms. PSMA-based triplet. PSMAddition added Lu-PSMA-617 to ADT + ARPI in PSMA-positive mCSPC and improved radiographic PFS (HR 0.72), with overall survival still maturing.
- How that sits next to chemotherapy triplets such as ARASENS (mature OS HR 0.68) is an open question. No head-to-head comparison so far.
–
- Perioperative therapy. PROTEUS showed perioperative apalutamide + ADT with radical prostatectomy can deepen pathologic response and improve metastasis-free survival.
- Whether this becomes routine perioperative care – for whom, for how long, and how it translates to radiation-managed high-risk disease – is still being worked out in real practice and guidelines.
–
- Kidney Cancer- intensifying adjuvant care carefully. LITESPARK-022 found adjuvant belzutifan plus pembrolizumab improved DFS versus pembrolizumab alone (HR 0.72; 24-month DFS 80.7% versus 73.7%), with higher grade ≥3 toxicity and immature OS.
- Another place where careful clinical judgment will help us choose the best regimen for individual patients.”
You can also read:
The Inaugural ESMO Genitourinary Cancers Asia 2027
